GT200600251A - Intermediarios utiles en la sintesis de moduladores de alquilquinolina y alquilquinazolina quinasa y metodos de sintesis relacionados. - Google Patents

Intermediarios utiles en la sintesis de moduladores de alquilquinolina y alquilquinazolina quinasa y metodos de sintesis relacionados.

Info

Publication number
GT200600251A
GT200600251A GT200600251A GT200600251A GT200600251A GT 200600251 A GT200600251 A GT 200600251A GT 200600251 A GT200600251 A GT 200600251A GT 200600251 A GT200600251 A GT 200600251A GT 200600251 A GT200600251 A GT 200600251A
Authority
GT
Guatemala
Prior art keywords
synthesis
alquilquinolina
alquilquinazolina
quinasa
modulators
Prior art date
Application number
GT200600251A
Other languages
English (en)
Inventor
Nand Baindur
Michael David Gaul
Kevin Douglas Kreutter
Christian Andrew Baumann
Alexander J Kim
Guozhang Xu
Robert W Tuman
Dana L Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200600251A publication Critical patent/GT200600251A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA A COMPUESTOS ALQUILQUINOLINA Y ALQUILQUINAZOLINA DE FÓRMULA I, AL USO DE DICHOS COMPUESTOS EN LA SÍNTESIS DE LOS INHIBIDORES DE LA PROTEÍNA TIROSINQUINASA, PARTICULARMENTE LOS INHIBIDORES DE FLT3 Y/O C-KIT Y/O TRKB. T2006
GT200600251A 2005-06-10 2006-06-08 Intermediarios utiles en la sintesis de moduladores de alquilquinolina y alquilquinazolina quinasa y metodos de sintesis relacionados. GT200600251A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68938405P 2005-06-10 2005-06-10
US73091905P 2005-10-27 2005-10-27

Publications (1)

Publication Number Publication Date
GT200600251A true GT200600251A (es) 2007-01-12

Family

ID=37038081

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600251A GT200600251A (es) 2005-06-10 2006-06-08 Intermediarios utiles en la sintesis de moduladores de alquilquinolina y alquilquinazolina quinasa y metodos de sintesis relacionados.

Country Status (18)

Country Link
US (1) US8071768B2 (es)
EP (1) EP1893598A1 (es)
JP (1) JP2009501135A (es)
KR (1) KR20080028912A (es)
AR (1) AR054386A1 (es)
AU (1) AU2006257945A1 (es)
BR (1) BRPI0611964A2 (es)
CA (1) CA2611242A1 (es)
CR (1) CR9652A (es)
EA (1) EA200800017A1 (es)
EC (1) ECSP077997A (es)
GT (1) GT200600251A (es)
IL (1) IL187692A0 (es)
NO (1) NO20080174L (es)
PE (1) PE20070014A1 (es)
TW (1) TW200716599A (es)
UY (1) UY29588A1 (es)
WO (1) WO2006135721A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825244B2 (en) * 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US8760507B2 (en) * 2008-08-05 2014-06-24 Inspectron, Inc. Light pipe for imaging head of video inspection device
WO2011078369A1 (ja) * 2009-12-25 2011-06-30 持田製薬株式会社 新規アリールウレア誘導体
BR112013006953A2 (pt) 2010-09-29 2016-07-26 Intervet Int Bv composto, composições farmacêutica e anti-helmíntica, uso de um composto, kit, e, método de tratamento de uma doença
CN103717591B (zh) 2011-07-27 2016-08-24 Ab科学有限公司 作为选择性蛋白激酶(c-kit)抑制剂的噁唑和噻唑衍生物
SG11201503959VA (en) * 2012-11-20 2015-06-29 Merial Inc Anthelmintic compounds and compositions and method of using thereof
RU2641106C2 (ru) * 2013-10-16 2018-01-16 Фуджифилм Корпорэйшн Соль азотсодержащего гетероциклического соединения или ее кристаллическая форма, фармацевтическая композиция и ингибитор flt3
US20170305857A1 (en) * 2013-12-20 2017-10-26 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
CN107205970A (zh) 2014-11-05 2017-09-26 弗莱塞斯生物科学公司 免疫调节剂
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
JP6412471B2 (ja) * 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
CN110950842B (zh) * 2018-09-27 2023-06-20 深圳微芯生物科技股份有限公司 具有吲哚胺-2,3-双加氧酶抑制活性的喹啉衍生物
CA3128085A1 (en) * 2018-12-21 2020-06-25 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Dna-pkcs inhibitors for increasing genome editing efficiency

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517005A (en) 1967-10-26 1970-06-23 Pfizer & Co C Certain 2- and 4-substituted quinazolines
GB1460389A (en) 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
JPS5976082A (ja) 1982-10-23 1984-04-28 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
GB8320958D0 (en) 1983-08-03 1983-09-07 Pfizer Ltd Quinazoline cardiac stimulants
US5300515A (en) 1991-01-31 1994-04-05 Kyorin Pharmaceutical Co., Ltd. Carbamic acid derivatives and method for preparing the same
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
KR19990007865A (ko) 1995-04-19 1999-01-25 스피겔알렌제이 약물 방출용 피복 스텐트
WO1997028118A1 (en) 1996-02-05 1997-08-07 Hoechst Celanese Corporation Process for preparing anthranilic acids
US5948786A (en) * 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
CA2250943A1 (en) 1996-04-12 1997-10-23 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
US5869669A (en) * 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
JP4073961B2 (ja) * 1996-10-01 2008-04-09 協和醗酵工業株式会社 含窒素複素環化合物
US5866562A (en) 1996-10-25 1999-02-02 Bayer Aktiengesellschaft Ring-bridged bis-quinolines
JP2002508366A (ja) 1997-12-12 2002-03-19 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー キノリンピペラジンおよびキノリンピペリジン誘導体、それらの製造方法、ならびに複合的５−ｈｔ１ａ、５−ｈｔ１ｂおよび５−ｈｔ１ｄ受容体アンタゴニストとしてのそれらの用途
DE19756388A1 (de) 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
AU1071301A (en) 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
AU2001293209A1 (en) 2000-08-18 2002-03-04 Cor Therapeutics, Inc. Nitrogenous heterocyclic compounds
AU2001293207A1 (en) 2000-08-18 2002-03-04 Cor Therapeutics, Inc. Nitrogenous heterocyclic compounds
CA2424689A1 (en) 2000-10-17 2002-04-25 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
WO2002048152A2 (en) 2000-12-12 2002-06-20 Neurogen Corporation Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
DE10109866A1 (de) 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
EP2048142A3 (en) 2001-04-26 2009-04-22 Eisai R&D Management Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
WO2003037347A1 (en) 2001-10-30 2003-05-08 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
WO2003057690A1 (en) 2001-12-27 2003-07-17 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
CA2473572C (en) 2002-02-01 2011-05-10 Astrazeneca Ab Quinazoline compounds
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
BR0312204A (pt) 2002-06-27 2005-04-26 Schering Ag Antagonista de receptor ccr5 de quinolina substituìda
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
NZ538715A (en) 2002-08-14 2007-07-27 Vertex Pharma Protein kinase inhibitors and uses thereof
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
WO2004039782A1 (ja) 2002-10-29 2004-05-13 Kirin Beer Kabushiki Kaisha Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
EP1565187A4 (en) 2002-11-13 2010-02-17 Novartis Vaccines & Diagnostic CANCER TREATMENT METHODS AND RELATED METHODS
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
US7226919B2 (en) 2002-12-18 2007-06-05 Vertex Pharmaceuticals Inc. Compositions useful as inhibitors of protein kinases
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
JP4845736B2 (ja) 2003-10-14 2011-12-28 アリゾナ ボード オブ リージェンツ オン ビハーフ ザ ユニバーシティー オブ アリゾナ プロテインキナーゼ阻害剤
KR101223914B1 (ko) 2003-11-21 2013-01-18 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators

Also Published As

Publication number Publication date
KR20080028912A (ko) 2008-04-02
BRPI0611964A2 (pt) 2009-01-27
AR054386A1 (es) 2007-06-20
UY29588A1 (es) 2006-10-02
ECSP077997A (es) 2008-01-23
CA2611242A1 (en) 2006-12-21
US20060281772A1 (en) 2006-12-14
AU2006257945A1 (en) 2006-12-21
CR9652A (es) 2008-09-09
WO2006135721A1 (en) 2006-12-21
JP2009501135A (ja) 2009-01-15
US8071768B2 (en) 2011-12-06
EP1893598A1 (en) 2008-03-05
IL187692A0 (en) 2008-08-07
EA200800017A1 (ru) 2008-08-29
NO20080174L (no) 2008-02-19
TW200716599A (en) 2007-05-01
PE20070014A1 (es) 2007-03-08

Similar Documents

Publication Publication Date Title
GT200600251A (es) Intermediarios utiles en la sintesis de moduladores de alquilquinolina y alquilquinazolina quinasa y metodos de sintesis relacionados.
EA200800701A1 (ru) 4-замещенные пирролидин-2-оны и их применение
HN2007000267A (es) Compuestos de 4-metil piridopirimidinoma
DOP2006000227A (es) Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas
UY30610A1 (es) Moduladores de mglur5
SV2006002232A (es) Inhibidores bace ref. x-16940
ECSP10010722A (es) Compuestos orgánicos
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
AR057253A1 (es) Anticuerpos anti-ox40l y metodos que los utilizan
NI201000059A (es) Inhibidores de la cinasa c-fms.
CR9649A (es) Aminopirimidinas como modulares de cinasa
ECSP077248A (es) Procedimiento para la preparación de dihidropteridinonas
SV2010003718A (es) Inhibidores de bace
HN2006016313A (es) Derivados de amida sustituida y metodos de uso
AR063188A1 (es) Compuestos intermediarios para la preparacion de trans -5-cloro-2-netil-2,3,3a,12b- tetrahidro-1h-dibenz (2,3:6,7)- oxepina (4,5c) pirrol
ECSP088884A (es) Compuestos heterociclicos fusionados y su uso como moduladores de mglur5
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
NO20071604L (no) Loxapinanaloger og fremgangsmater for anvendelse derav.
GT200600248A (es) Aminopirimidinas como moduladores de quinasas
DOP2005000010A (es) Inhibidores de quinasa
ECSP088252A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
UY29221A1 (es) Derivados de octahidropirrolo(3,4-c)pirrol
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
CR11584A (es) Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina